The role of endocannabinoids in pain modulation

Fundamental and Clinical Pharmacology

Volumn 27, Issue 1, 2013, Pages 64-80

  Zogopoulos, Panagiotis ^a   Vasileiou, Ioanna ^a   Patsouris, Efstratios ^a   Theocharis, Stamatios E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

2 arachidonoylglycerol; Analgesia; Anandamide, N arachidonoylethanolamine; Antinociception; CB receptors; Endocannabinoids

Indexed keywords

7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; ARVANIL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; GAMMA INTERFERON; INTERLEUKIN 6; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLODYNIA; ANALGESIC ACTIVITY; BIOSYNTHESIS; BRAIN CORTEX; BRAIN STEM; BURNING SENSATION; CEREBELLUM; COUGHING; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRY EYE; GABAERGIC TRANSMISSION; HIPPOCAMPUS; HUMAN; HYPERALGESIA; LIMBIC SYSTEM; METABOLISM; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANALGESIA; ANIMALS; BIOLOGICAL TRANSPORT; ENDOCANNABINOIDS; ENDOTHELIUM, VASCULAR; HUMANS; LIGANDS; NEUROGLIA; NEURONS; PAIN PERCEPTION; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 84872425727     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12008     Document Type: Review

References (196)

1. Pertwee R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. (2005) 7 625-654.
2. Grotenhermen F. "Cannabinoids". Curr. Drug Targets CNS Neurol. Disord. (2005) 4 507-530.
3. Lichtman A.H. SR141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur. J. Pharmacol. (2000) 404 175-179.
4. Rodriguez de Fonseca F., Del Arco I., Bermudez-Silva F.J., Bilbao A., Cippitelli A., Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. (2005) 40 2-14.
5. Izzo A.A., Sharkey K.A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Ther. (2010) 126 21-38.
6. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346 561-564.
7. Guzman M., Sanchez C., Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J. Mol. Med. (2001) 78 613-625.
8. Devane W.A., Hanus L., Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258 1946-1949.
9. Bisogno T., Martire A., Petrosino S., Popoli P., Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem. Int. (2008) 52 307-313.
10. Bari M., Battista N., Fezza F., Gasperi V., Maccarrone M. New insights into endocannabinoid degradation and its therapeutic potential. Mini. Rev. Med. Chem. (2006) 6 257-268.
11. Rajesh M., Mukhopadhyay P., Batkai S. et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am. J. Physiol. Heart Circ. Physiol. (2007) 293 610-619.
12. Rajesh M., Mukhopadhyay P., Hasko G., Huffman J.W., Mackie K., Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-α-induced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol. (2008) 153 347-357.
13. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. (2003) 4 873-884.
14. Herkenham M. Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res. Monogr. (1991) 112 129-145.
15. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. (1991) 11 563-583.
16. Farquhar-Smith W.P., Egertova M., Bradbury E.J., McMahon S.B., Rice A.S., Elphick M.R. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol. Cell. Neurosci. (2000) 15 510-521.
17. Iversen L. Cannabis and the brain. Brain (2003) 126 1252-1270.
18. Matyas F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U., Freund T.F. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience (2006) 137 337-361.
19. Carrier E.J., Kearn C.S., Barkmeier A.J. et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. (2004) 65 999-1007.
20. Gong J.P., Onaivi E.S., Ishiguro H. et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. (2006) 1071 10-23.
21. Sheng W.S., Hu S., Min X., Cabral G.A., Lokensgard J.R., Peterson P.K. Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia (2005) 49 211-219.
22. Onaivi E.S., Ishiguro H., Gong J.P. et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci. (2006) 1074 514-536.
23. Cabral G.A., Raborn E.S., Griffin L., Dennis J., Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br. J. Pharmacol. (2008) 153 240-251.
24. Cabral G.A., Griffin-Thomas L. Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr. Metab. Immune Disord. Drug Targets (2008) 8 159-172.
25. Sagredo O., Gonzalez S., Aroyo I. et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia (2009) 57 1154-1167.
26. Golech S.A., McCarron R.M., Chen Y. et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. (2004) 132 87-92.
27. Van Sickle M.D., Duncan M., Kingsley P.J. et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 310 329-332.
28. Wotherspoon G., Fox A., McIntyre P., Colley S., Bevan S., Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience (2005) 135 235-245.
29. Ashton J.C., Friberg D., Darlington C.L., Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci. Lett. (2006) 396 113-116.
30. Galiegue S., Mary S., Marchand J. et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. (1995) 232 54-61.
31. Schatz A.R., Lee M., Condie R.B., Pulaski J.T., Kaminski N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. (1997) 142 278-287.
32. Rajesh M., Pan H., Mukhopadhyay P. et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J. Leukoc. Biol. (2007) 82 1382-1389.
33. McAllister S.D., Glass M. CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66 161-171.
34. Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. (2006) 46 101-122.
35. Huang S.M., Bisogno T., Trevisani M. et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl Acad. Sci. USA (2002) 99 8400-8405.
36. Porter A.C., Sauer J.M., Knierman M.D. et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. (2002) 301 1020-1024.
37. Nagarkatti P., Pandey R., Rieder S.A., Hegde V.L., Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem (2009) 1 1333-1349.
38. Sugiura T., Kondo S., Kishimoto S. et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor-comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. (2000) 275 605-612.
39. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature (1995) 376 590-594.
40. Sagan S., Venance L., Torrens Y., Cordier J., Glowinski J., Giaume C. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. J. Neurosci. (1999) 11 691-699.
41. Di Marzo V., Bisogno T., De Petrocellis L. Endocannabinoids: new targets for drug development. Curr. Pharm. Des. (2000) 6 1361-1380.
42. Szoke E., Balla Z., Csernoch L., Czeh G., Szolcsanyi J. Interacting effects of capsaicin and anandamide on intracellular calcium in sensory neurones. NeuroReport (2000) 11 1949-1952.
43. Mechoulam R., Ben-Shabat S., Hanus L. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50 83-90.
44. Sugiura T., Kondo S., Sukagawa A. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215 89-97.
45. Di Marzo V., Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. (2007) 18 129-140.
46. Vemuri V.K., Janero D.R., Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol. Behav. (2008) 93 671-686.
47. Janero D.R., Vadivel S.K., Makriyannis A. Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. Int. Rev. Psychiatry (2009) 21 122-133.
48. Bisogno T., Melck D., Bobrov M. et al. N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. (2000) 1 817-824.
49. Walker M.J., Krey F.J., Chu C.J., Huang S.M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem. Phys. Lipids (2002) 121 159-172.
50. Hanus L. et al. 2-Arachidonoyl glycerol ether, endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl Acad. Sci. U S A (2001) 98 3662-3665.
51. Di Marzo V., Bisogno T., De Petrocellis L. et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. (1999) 264 258-267.
52. Longhua Z., Meina W., Bisogno Tiziana B., Di Marzo V., Alger B.E. Endocannabinoids Generated by Ca2 + or by Metabotropic Glutamate Receptors Appear to Arise from Different Pools of Diacylglycerol Lipase. PLoS One (2011) 6 16305.
53. van Der Stelt M., Veldhuis W.B., van Haaften G.W. et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. (2001) 21 8765-8771.
54. Garcia-Ovejero D., Arevalo-Martin A., Petrosino S. et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol. Dis. (2009) 33 57-71.
55. Ahn K., McKinney M.K., Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev. (2008) 108 1687-1707.
56. Lovinger D.M. Presynaptic modulation by endocannabinoids. Handb. Exp. Pharmacol. (2008) 184 435-477.
57. Lopez R., Mateos Vicente B., Romero-Zerbo S.Y. et al. Estradiol decreases cortical reactive astrogliosis after brain injury by a mechanism involving cannabinoid receptors. Cereb. Cortex (2011) 21 2046-2055.
58. Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maasson J.L., Schmid H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. (1995) 375 143-147.
59. Hansen H.H., Schmid P.C., Bittigau P. et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. (2001) 78 1415-1427.
60. Natarajan V., Schmid P.C., Reddy P.V., Zuzarte-Augustin M.L., Schmid H.H. Biosynthesis of Nacylethanolamine phospholipids by dog brain preparations. J. Neurochem. (1983) 41 1303-1312.
61. Natarajan V., Schmid P.C., Reddy P.V., Schmid H.H. Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J. Neurochem. (1984) 41 1303-1312.
62. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. (1997) 17 1226-1242.
63. Giuffrida A., Parsone L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., Pomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. (1999) 2 358-363.
64. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. (2003) 17 2750-2754.
65. Sugiura T., Kishimoto S., Oka S., Gokoh M., Wake K. Metabolism and physiological significance of anadamide and 2-arachidonoylglycerol, endogenous cannabinoid receptor ligands, in: Fonteh A.N., Wykle R.L. (Eds), Arachidonate remodeling and inflammation, Birkhδuser Verlag, Basel, Switzerland, 2004, pp. 211-237.
66. Mechoulam R., Shohami E. Endocannabinoids and traumatic brain injury. Mol. Neurobiol. (2007) 36 68-74.
67. Miller A.S., Walker J.M. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur. J. Pharmacol. (1995) 279 179-185.
68. Croxford J.L., Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases. J. Neuroimmunol. (2005) 166 3-18.
69. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature (1996) 384 83-87.
70. Fegley D., Kathuria S., Mercier R. et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl Acad. Sci. USA (2004) 101 8756-8761.
71. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. (2007) 14 1347-1356.
72. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol. (2008) 160 1-24.
73. Fu J., Bottegoni G., Sasso O. et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat. Neurosci. (2011) 15 64-69.
74. Egertova M., Giang D.K., Cravatt B.F., Elphick M.R. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. Biol. Sci. (1998) 265 2081-2085.
75. Karbarz M.J., Luo L., Chang L. et al. Biochemical and Biological Properties of 4-(3-phenyl-[1, 2, 4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a Mechanism-Based Inhibitor of Fatty Acid Amide Hydrolase. Anesth. Analg. (2009) 108 316-329.
76. Cravatt B.F., Demarest K., Patricelli M.P. et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA (2001) 98 9371-9376.
77. Katayama K., Ueda N., Katoh I., Yamamoto S. Equilibrium in the hydrolysis and synthesis of cannabimimetic anandamide demonstrated by a purified enzyme. Biochim. Biophys. Acta (1999) 1440 205-214.
78. Kurahashi Y., Ueda N., Suzuki H., Suzuki M., Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochem. Biophys. Res. Commun. (1997) 237 512-515.
79. Arreaza G., Devane W., Omeir R.L. et al. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neurosci. Lett. (1997) 234 59-62.
80. Walter L., Dinh T., Stella N. ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. J. Neurosci. (2004) 24 8068-8074.
81. Goparaju S.K., Udea N., Yamaguchi H., Yamamoto S. Anandamide aminohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. (1998) 422 69-73.
82. Maione S., De Petrocellis L., de Novellis V. et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. (2007) 150 766-781.
83. Yu M., Ives D., Ramesha C.S. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem. (1997) 272 21181-21186.
84. Sang N., Chen C. Lipid signaling and synaptic plasticity. Neuroscientist (2006) 2 425-434.
85. Sang N., Zhang J., Chen C. COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J. Neurochem. (2007) 102 1966-1977.
86. Ross R.A., Craib S.J., Stevenson L.A. et al. Pharmacological characterization of the anandamide cyclooxygenase metabolite:prostaglandin E2 ethanolamide. J. Pharmacol. Exp. Ther. (2002) 301 900-907.
87. Nirodi C.S., Crew B.C., Kozak K.R., Rorrow J.D., Marnett L.J. The glyceryl ester of prostaglandin E2 mobilize calcium and activates signal transduction in RAW 264.7 cells. Proc. Natl Acad. Sci. USA (2004) 101 1840-1845.
88. Kozak K.R., Prusakiewicz J.L., Marnett L.J. Oxidative metabolism of endocannabinoids by COX-2. Curr. Pharmaceut. Design (2004) 10 659-667.
89. Patrignani P., Tacconelli S., Sciulli M.G., Capone M.L. New insights into COX-2 biology and inhibition. Brain Res. Rev. (2005) 48 352-359.
90. Hengartner M.O. The biochemistry of apoptosis. Nature (2000) 407 770-776.
91. Shohami E., Beit-Yannai E., Horowitz M., Kohen R. Oxidative stress in closed-head injury: brain antioxidant capacity as an indicator of functional outcome. J. Cereb. Blood Flow Metab. (1997) 17 1007-1019.
92. Shohami E., Gallily R., Mechoulam R., Bass R., Ben Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J. Neuroimmunol. (1997) 72 169-177.
93. Cabral G.A., Harmon K.N., Carlisle S.J. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv. Exp. Med. Biol. (2001) 493 207-214.
94. Molina-Holgado F., Molina-Holgado E., Guaza C. The endogenous cannabinoid anandamide potentiates IL-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor- mediated pathway. FEBS Lett. (1998) 433 139-142.
95. Choi S., Lovinger D.M. Metabotropic glutamate receptor modulation of voltage-gated Ca2 + channels involves multiple receptor subtypes in cortical neurons. J. Neurosci. (1996) 16 36-45.
96. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. (1997) 78 43-50.
97. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. (1996) 16 4322-4334.
98. van der Stelt M., Veldhuis W.B., Maccarrone M. et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol. Neurobiol. (2002) 26 317-346.
99. Mehta S.L., Manhas N., Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev. (2007) 54 34-66.
100. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. (1984) 26 532-538.
101. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. (2006) 29 37-76.
102. Derkinderen P., Toutant M., Burgaya F. et al. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science (1996) 273 1719-1722.
103. Derkinderen P., Valjent E., Toutant M. et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. (2003) 23 2371-2382.
104. Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer (2003) 3 745-755.
105. Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol. Ther. (2006) 111 114-144.
106. Zygmunt P.M., Peterson J., Andersson D.A. et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 400 452-457.
107. De Petrocellis L., Di Marzo V. Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci. (2005) 77 1651-1666.
108. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors - evidence for a protective role of cannabinoid receptors. J. Biol. Chem. (2000) 275 31938-31945.
109. Cernak I., Vink R., Natale J. et al. The "dark side" of endocannabinoids: a neurotoxic role for anandamide. J. Cereb. Blood Flow Metab. (2004) 24 564-578.
110. Szallasi A., Blumberg P.M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol. Rev. (1999) 51 159-212.
111. Marinelli S., Vaughan C.W., Christie M.J., Connor M. Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J. Physiol. (2002) 543 531-540.
112. Yue H.Y., Fujita T., Kawasaki Y., Kumamoto E. AM404 enhances the spontaneous release of L-glutamate in a manner sensitive to capsazepine in adult rat substantia gelatinosa neurones. Brain Res. (2004) 1018 283-287.
113. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids (2000) 108 169-190.
114. Lombard C., Nagarkatti M., Nagarkatti P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin. Immunol. (2007) 122 259-270.
115. Jacobsson S.O., Rongard E., Stridh M., Tiger G., Fowler C.J. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem. Pharmacol. (2000) 60 1807-1813.
116. Panikashvili D., Mechoulam R., Beni S.M., Alexandrovich A., Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J. Cereb. Blood Flow Metab. (2005) 25 477-484.
117. Sarker K.P., Obara S., Nakata M., Kitajima I., Maruyama I. Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. (2000) 472 39-44.
118. Eljaschewitsch E., Witting A., Mawrin C. et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (2006) 49 67-79.
119. Pitler T.A., Alger B.E. Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism. Neuron (1994) 13 1447-1455.
120. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 410 588-592.
121. Wilson R.I., Kunos G., Nicoll R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron (2001) 31 453-462.
122. Alsasua del Valle A. Implication of cannabinoids in neurological diseases. Cell. Mol. Neurobiol. (2006) 26 579-591.
123. Trettel J., Levine E.S. Endocannabinoids mediate rapid retrograde signaling at interneuron right-arrow pyramidal neuron synapses of the neocortex. J. Neurophysiol. (2003) 89 2334-2338.
124. Kreitzer A.C., Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron (2001) 29 717-727.
125. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. (2003) 83 1017-1066.
126. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl Acad. Sci. USA (1992) 89 3825-3829.
127. Kim J., Alger B.E. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat. Neurosci. (2004) 7 697-698.
128. Katona I., Urban G.M., Wallace M. et al. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. (2006) 26 5628-5637.
129. Yoshida T., Fukaya M., Uchigashima M. et al. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J. Neurosci. (2006) 26 4740-4751.
130. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science (2002) 296 678-682.
131. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. (2002) 68 247-286.
132. Tsou K., Lowitz K.A., Hohmann A.G. et al. Suppression of noxious stimulus evoked expression of fos-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience (1995) 70 791-798.
133. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. (1997) 221 157-160.
134. Wang L.X., Wang Z.J. Animal and cellular models of chronic pain. Adv. Drug Deliv. Rev. (2003) 55 949-965.
135. Jaggi A.S., Jain V., Singh N. Animal models of neuropathic pain. Fundam. Clin. Pharmacol. (2011) 25 1-28.
136. Walker J.M., Huang S.M. Cannabinoid analgesia. Pharmacol. Ther. (2002) 95 127-135.
137. Martin W.J., Patrick S.L., Coffin P.O., Tsou K., Walker J.M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. (1995) 56 2103-2109.
138. Martin L.J., Al-Abdulla N.A., Brambrink A.M., Kirsch J.R., Sieber F.E., Portera-Cailliau C. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res. Bull. (1998) 46 281-309.
139. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain (1999) 82 199-205.
140. Martin W.J., Coffin P.O., Attias E., Balinsky M., Tsou K., Walker J.M. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. (1999) 822 237-242.
141. Treede R.D., Kenshalo D.R., Gracely R.H., Jones A.K. The cortical representation of pain. Pain (1999) 79 105-111.
142. Hoot M.R., Sim-Selley L.J., Poklis J.L., Rehab A. Abdullah, Krista L. Scoggins, Dana E. Selley, William L. Dewey. Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice. Brain Res. (2010) 1339 18-25.
143. Martin B.R., Lichtman A.H. Cannabinoid transmission and pain perception. Neurobiol. Dis. (1998) 5 447-461.
144. Martin W.J., Tsou K., Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett. (1998) 242 33-36.
145. Martin B.R., Thomas B.F., Razdan R.K. Structural requirements for cannabinoid receptor probes, in: Pertwee R.G. (Ed.), Cannabinoid receptors, Academic Press, London, 1995b, pp. 35-85.
146. Nackley A.G., Suplita R.L., Hohmann A.G. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 117 659-670.
147. Sagar D.R., Kelly S., Millns P.J., O'Shaughnessey C.T., Kendall D.A., Chapman V. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur. J. Neurosci. (2005) 22 371-379.
148. Khanna N., Malhotra R.S., Mehta A.K., Garg G.R., Halder S., Sharma K.K. Interaction of morphine and potassium channel openers on experimental models of pain in mice. Fundam. Clin. Pharmacol. (2011) 25 479-484.
149. Bloom A.S., Dewey W.L., Harris L.S., Brosius K.K. 9-nor-9bhydroxyhexahydrocannabinol a cannabinoid with potent antinociceptive activity: comparisons with morphine. J. Pharmacol. Exp. Ther. (1997) 200 263-270.
150. Sofia R.D., Nalepa S.D., Harakal J.J., Vassar H.B. Anti-edema and analgesic properties of D9-tetrahydrocannabinol THC. J. Pharmacol. Exp. Ther. (1973) 186 646-655.
151. Formukong E.A., Evans A.T., Evans F.J. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation (1988) 12 361-371.
152. Walczak J.S., Pichette V., Leblond F., Desbiens K., Beaulieu P. Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J. Neurosci. Res. (2006) 83 1310-1322.
153. Costa B., Colleoni M., Trovato A.E., Conti S., Pomelli F., Franke C. Anandamide uptake and hydrolysis as targets for the treatment of neuropathic pain: effect of AM404 and URB597 in rats with chronic constriction injury of the sciatic nerve. XV Symposium on the Cannabinoids, Clearwater Beach, FL, 24-29 June 2005, p. 33.
154. Costa B., Siniscalco D., Trovato A.E. et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br. J. Pharmacol. (2006) 148 1022-1032.
155. Ledent C., Valverde O., Cossu G. et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 283 401-404.
156. Agarwal N., Pacher P., Tegeder I. et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. (2007) 10 870-879.
157. Petrosino S., Palazzo E., de Novellis V. et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology (2007) 52 415-422.
158. Kanai Y., Nakazato E., Fujiuchi A., Hara T., Imai A. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology (2005) 49 977-984.
159. Kinsey S.G., Long J.Z., O'Neal S.T. et al. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J. Pharmacol. Exp. Ther. (2009) 330 902-910.
160. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain (1998) 75 111-119.
161. Bisogno T., Ligresti A., Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol. Biochem. Behav. (2005) 81 224-238.
162. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. (1992) 262 10-18.
163. Cichewicz D.L., Martin Z.L., Smith F.L., Welch S.P. Enhancement of m opioid antinociception by oral D9-tetrahydrocannabinol: dose-response analysis and receptor identification. J. Pharmacol. Exp. Ther. (1999) 289 859-867.
164. González-Rodríguez S., Llames S., Hidalgo A., Baamonde A., Menéndez L. Potentiation of acute morphine-induced analgesia measured by a thermal test in bone cancer-bearing mice. Fundam. Clin. Pharmacol. (2012) 26 363-372.
165. Goya P., Jagerovic N., Hernandez-Folgado L., Martin M.I. Cannabinoids and neuropathic pain. Mini Rev. Med. Chem. (2003) 3 765-772.
166. Cravatt B.F., Lichtman A.H. The endogenous cannabinoid system and its role in nociceptive behavior. J. Neurobiol. (2004) 61 149-160.
167. Bridges D., Rice A.S.C., Egertova M., Elphick M.R., Winter J. The cannabinoid CB l receptor is localised predominantly on N52 within the rat dorsal root ganglion. Soc. Neurosci. Abstr. (2001) 27 716.3.
168. Mauler F., Hinz V., Augstein K.H., Fassbender M., Horvath E. Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res. (2003) 989 99-111.
169. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. (1999) 6 635-664.
170. Besse D., Lombard M.C., Perrot S., Besson J.M. Regulation of opioid binding sites in the superficial dorsal horn of the rat spinal cord following loose ligation of the sciatic nerve: comparison with sciatic nerve section and lumbar dorsal rhizotomy. Neuroscience (1992) 50 921-933.
171. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55, 212-2. Neurosci. Lett. (1998) 257 119-122.
172. Carlini E.A. The good and the bad effects of (-)trans-delta-9-tetrahydrocannabinol (Delta 9 THC) on humans. Toxicon (2004) 44 461-467.
173. Ware M., Wang T., Shapiro S., Robinson A. et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ (2010) 182 694-701.
174. Lichtman A.H., Peart J., Poklis J.L. et al. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur. J. Pharmacol. (2000) 399 141-149.
175. Landfield P.W., Cadwallader L.B., Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res. (1988) 443 47-62.
176. Gardner E.L. Endocannabinoids ignaling system andb rain reward: emphasis on dopamine. Pharmacol. Biochem. Behav. (2005) 81 263-284.
177. Kreutz S., Koch M., Bottger C., Ghadban C., Korf H.W., Dehghani F. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal- cannabidiol sensitive receptors on microglial cells. Glia (2009) 57 286-294.
178. Nagayama T., Sinor A.D., Simon R.P. et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. (1999) 19 2987-2995.
179. Marsicano G., Goodenough S., Monory K. et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 302 84-88.
180. Stella N. Cannabinoid signaling in glial cells. Glia (2004) 48 267-277.
181. Rice A.S.C., Farquhar-Smith W.P., Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot. Essent. FattyAcids (2002) 66 243-256.
182. Blake D.R., Robson P., Ho M., Jubb R.W., McCabe C.S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) (2006) 45 50-52.
183. Ashton J.C., Milligan E.D. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr. Opin. Investig. Drugs (2008) 9 65-75.
184. Wallace M., Schulteis G., Atkinson J.H. et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology (2007) 107 785-796.
185. Johnson J.R., Burnell-Nugent M., Lossignol D., Ganae-Motan E.D., Potts R., Fallon M.T. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain. Symptom. Manag. (2010) 39 167-179.
186. Abrams D.I., Jay C.A., Shade S.B. et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology (2007) 68 515-521.
187. Pertwee R.G., Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66 101-121.
188. Pollmann W., Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs (2008) 22 291-324.
189. Benito C., Nunez E., Tolon R.M. et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. (2003) 23 11136-11141.
190. Maccarrone M., Gubellini P., Bari M. et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. (2003) 85 1018-1025.
191. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. (2005) 25 1904-1913.
192. Micale V., Mazzola C., Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol. Res. (2007) 56 382-392.
193. Wennerberg M., Balendran A., Clapham J.C., Vauquelin G. Unravelling the complex dissociation of [3H]-rimonabant from plated CB1 cannabinoid receptor-expressing cells. Fundam. Clin. Pharmacol. (2010) 24 181-187.
194. Wennerberg M., Cheng L., Hjorth S., Clapham J.C., Balendran A., Vauquelin G. Binding properties of antagonists to Cannabinoid receptors in intact cells. Fundam. Clin. Pharmacol. (2011) 25 200-210.
195. Palmer J.A., Higuera E.S., Chang L., Chaplan S.R. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. Neuroscience (2008) 154 1554-1561.
196. Panikashvili D., Shein N.A., Mechoulam R. et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. (2006) 22 257-264.